--- title: 'Associate Director / Director, Clinical Pharmacology at Iambic Therapeutics, Inc' canonical: 'https://feeny.ai/job/associate-director-director-clinical-pharmacology-iambic-therapeutics-inc-san-je8hv9zyhrrm' type: 'job' last_seen: '2026-09-16' --- # Associate Director / Director, Clinical Pharmacology at Iambic Therapeutics, Inc - **Company:** Iambic Therapeutics, Inc - **Location:** San Diego, CA - **Employment:** full-time - **Work type:** onsite - **Posted:** 2026-08-20 - **Last confirmed live:** 2026-09-16 - **Apply:** https://jobs.ashbyhq.com/iambic-therapeutics/955ee88d-3048-406f-80aa-e9b16c7b6a13 ## Job description ## JOB SUMMARY The Associate Director/Director will be responsible for designing and executing clinical pharmacology strategy for oncology small-molecule programs, including PK/PD study design, dose selection and optimization, and the use of modeling and simulation approaches (e.g., PBPK, population PK) to inform program decisions. This role partners closely with Clinical Development, DMPK, Biostatistics, and Regulatory Affairs to author and review protocols and clinical pharmacology sections of regulatory submissions (IND/IMPD, briefing documents, and CTD modules) and to prepare responses to health authority queries. The role also contributes to drug-drug interaction, organ impairment, and cardiac safety (QT) assessment strategies for small-molecule oncology assets, ensuring alignment with current FDA/EMA/ICH guidance (including ICH M12), and may mentor junior scientists within the function. ## KEY RESPONSIBILITIES - Represent Clinical Pharmacology line function and work on multi-disciplinary oncology small-molecule program teams (clinical, DMPK, regulatory, biometrics, CMC, etc.), supporting programs from late-stage discovery and IND-enabling activities through Phase 1 dose escalation/expansion and beyond. - Independently analyze, interpret and report clinical PK, PK/PD, and exposure-response data for oncology small-molecule assets as a member of multidisciplinary development program teams. - Partner with Clinical Development to design clinical pharmacology components of oncology studies, including first-in-human dose escalation/expansion, drug-drug interaction, hepatic/renal impairment, food-effect, and cardiac safety (ECG/QT) studies, and combination-therapy dosing strategies. - Apply quantitative approaches (e.g., PBPK, population PK, exposure-response modeling) to inform dose selection and DDI risk assessment, with working knowledge of relevant software (e.g., SimCyp, Phoenix WinNonlin, NONMEM, R) and current regulatory frameworks (e.g., ICH M12, FDA DDI guidance). - Write and review relevant sections of regulatory and scientific documentation including Clinical Study Protocols, IBs, SOPs, Statistical Analysis Plans and Clinical Study Reports. - Maintain a working knowledge of pharmacology, biology, therapeutics, drug metabolism, bioanalysis, and biopharmaceutics. - Review and author scientific publications, abstracts, posters - Maintain a positive, results-orientated work environment, building partnerships and modeling teamwork, and communicating to the team in an open, balanced and objective manner. ## QUALIFICATIONS - PhD or equivalent in Pharmacology/Biomedicine/Biochemistry or related scientific discipline with a minimum 5 years of relevant experience within a pharmaceutical industry, contract research, or clinical research. - Experience with clinical development of oncology small-molecule therapeutics is highly desirable, including familiarity with dose-escalation/expansion trial designs and combination-therapy regimens. - Proficiency using Phoenix Winnonlin for non-compartmental analysis - Working knowledge of PBPK modeling and current DDI regulatory frameworks (e.g., ICH M12, FDA guidance) is highly desirable. - Hands on clinical pharmacology related work experience in regulatory and scientific documentation writing including Clinical Study Protocols, SOPs, Statistical Analysis Plans and Clinical Study Reports, as well as regulatory documents. - Familiarity with PK bioanalytical methods development and validation is an asset - Ability to manage multiple projects, prioritize work effectively to meet deadlines, anticipate potential problems within project plans and effectively communicate alternatives. - Strong communication skills, with the ability to work collaboratively as a member of a cross-functional team. ## ABOUT IAMBIC THERAPEUTICS Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at [iambic.ai](http://iambic.ai). ## MISSION & CORE VALUES Our mission is to deliver better medicines through innovations in AI-based discovery technologies. The culture and work at Iambic Therapeutics are profoundly strengthened by the diversity of our people and our differences in background, culture, national origin, religion, sexual orientation, and life experiences. We are committed to building an inclusive environment where a diverse group of talented humans work together to discover therapeutics and create technologies. ## PAY AND BENEFITS We offer industry leading competitive pay, company paid healthcare, flexible spending accounts, voluntary life insurance, 401K matching, and uncapped vacation to our team. We are in a brand-new state-of-the art facility in beautiful San Diego with an onsite gym, dining, and easy access to great places to live and play. ## About Iambic Therapeutics, Inc ## Company Overview - **One-liner**: Iambic Therapeutics is a clinical‑stage biotechnology company that uses an AI‑driven platform to discover and develop novel small‑molecule medicines for oncology and other diseases. - **Entity Type**: Private (late‑stage venture‑backed) - **Headquarters**: San Diego, California, United States - **Founded**: 2020 - **Founders**: Not explicitly named in available sources; leadership includes a Co‑Founder & CEO and a Co‑Founder & CTO. ## Core Business - **Primary industries**: Biotechnology, AI‑powered drug discovery, oncology therapeutics - **Target customers**: B2B partnerships with pharmaceutical companies (e.g., Bayer) and, ultimately, patients through a wholly‑owned pipeline of clinical‑stage candidates - **Mission**: *“Better technology for better medicines”* – using machine learning and automation to transform the creation of new therapeutics ## Products & Services - **Enchant Platform**: A multi‑modal transformer AI that breaks down data barriers between preclinical and clinical R&D, enabling rapid molecular design. - **NeuralPLexer**: A co‑folding AI technology that predicts protein‑ligand structures to guide drug design. - **Automated High‑Throughput Experimentation**: AI‑driven robotics that generate new biological data from novel molecular designs on a weekly cadence. - **IAM1363** (HER2 inhibitor): A highly selective, brain‑penetrant tyrosine kinase inhibitor for HER2‑driven cancers; currently in Phase 1b clinical studies. - **IAM‑C1** (CDK2/4 dual inhibitor): A potential first‑in‑class selective inhibitor for HR+/HER2‑ metastatic breast cancer (preclinical). - **IAM‑K1** (KIF18A inhibitor): A potential best‑in‑class allosteric inhibitor for triple‑negative breast cancer, ovarian cancer, and other solid tumors (preclinical). - **Undisclosed programs**: Additional wholly‑owned candidates across multiple target classes and mechanisms. ## Market Standing - **Valuation**: Not publicly disclosed - **Key Metric**: **Total funding** – $330.8 M (including a $100 M Series B in Oct 2023, a $50 M Series B extension in Apr 2024 led by EXOR N.V. and Mubadala Capital, and a $127.8 M venture round in Nov 2025) - **Notable Investors/Partners**: EXOR N.V., Mubadala Capital, Nexus Venture, Bayer (collaboration in AI drug discovery), and a Scientific Advisory Board including Nobel Laureate Frances Arnold (Caltech) - **Growth Signals**: - Headcount of **117** (64.5 % year‑over‑year growth) - Active job postings: **18** (+200 % quarterly, +50 % yearly) - Pipeline advanced from program launch to IND in **2 years** (vs. 6‑year industry average for IAM1363) - Broad platform applicability demonstrated across orthosteric, allosteric, and protein‑protein interaction modalities ## Competitive Advantages - **Speed**: AI‑driven platform can deliver development candidates to clinical trials in roughly one‑third the industry average time. - **Selectivity & Differentiated Profiles**: IAM1363 shows > 5000‑fold selectivity against EGFR, avoiding EGFR‑driven toxicity; IAM‑C1 targets CDK2/4 with a novel selectivity profile. - **Broad Platform Applicability**: Platform has produced leads across diverse protein classes and mechanisms (orthosteric, allosteric, PPI modulators). - **Integration of AI and Drug Hunting**: Tightly integrated team of AI experts and seasoned drug hunters, with a culture of “audacity” that tackles hard chemistry problems. ## Strategic Focus - Advancing the clinical pipeline: IAM1363 Phase 1b, preparing IAM‑C1 and IAM‑K1 for IND‑enabling studies. - Expanding platform partnerships (e.g., Bayer collaboration). - Scaling the organization: actively hiring in ML science, computational chemistry, medicinal chemistry, and clinical operations. - Exploring new therapeutic areas and target classes through the Enchant and NeuralPLexer technologies. ## Why Work Here - **Culture**: Values of **Respect**, **Collaboration**, and **Audacity** – cross‑functional teamwork with resilience and optimism; a flat, high‑trust environment. - **Work Model**: Based in La Jolla/San Diego, CA; the company emphasizes on‑site collaboration for drug‑discovery and lab‑based roles; remote/hybrid policy not explicitly stated. - **Team Growth**: Rapidly scaling (headcount +64 % YoY) with a strong pipeline of open roles in ML, computational chemistry, drug product development, and clinical operations. - **Cutting‑Edge Work**: Opportunity to work at the intersection of frontier AI (large multimodal models, agentic data pipelines) and real‑world drug discovery that reaches patients. - **Leadership & Mentorship**: Advisory board includes Nobel laureate and former NVIDIA AI director; close integration of AI and biology. ## Sources 1. [iambic.ai](https://www.iambic.ai/) – Homepage, platform, and corporate overview 2. [iambic.ai/about](https://www.iambic.ai/about) – Leadership, advisory board, investors 3. [iambic.ai/pipeline](https://www.iambic.ai/pipeline) – Pipeline details (IAM1363, IAM‑C1, IAM‑K1) 4. [iambic.ai/careers](https://www.iambic.ai/careers) – Careers page, values, open positions 5. [linkedin.com/company/iambic-ai](https://www.linkedin.com/company/iambic-ai) – Company stats (headcount 117, $3.4M revenue, $330.8M funding, funding rounds, employee growth) ## Other roles at Iambic Therapeutics, Inc - [Associate Director, Procurement](https://feeny.ai/job/associate-director-procurement-iambic-therapeutics-inc-san-diego-qcw4jt4y5w2k) — San Diego, CA - [Sr Manager, FP&A - Discovery R&D](https://feeny.ai/job/sr-manager-fp-a-discovery-r-d-iambic-therapeutics-inc-san-diego-sznt8xkbx741) — San Diego, CA - [Director, Compensation, Benefits and HR Systems](https://feeny.ai/job/director-compensation-benefits-and-hr-systems-iambic-therapeutics-inc-san-diego-nkd5b8fqk3mh) — San Diego, CA - [Associate Medical Director/Medical Director](https://feeny.ai/job/associate-medical-director-medical-director-iambic-therapeutics-inc-united-nrtdmj0ywpmb) — United States - [Research Scientist I/II, Purification Sciences](https://feeny.ai/job/research-scientist-i-ii-purification-sciences-iambic-therapeutics-inc-san-diego-bbfkrw5by7v1) — San Diego, CA - [Senior Associate Scientist I/II, Purification Sciences](https://feeny.ai/job/senior-associate-scientist-i-ii-purification-sciences-iambic-therapeutics-inc-7gpy6fbbe0br) — San Diego, CA - [Director/Senior Director, Immunology](https://feeny.ai/job/director-senior-director-immunology-iambic-therapeutics-inc-san-diego-pc8aedpavc67) — San Diego, CA - [Software Engineer — Agentic data pipelines](https://feeny.ai/job/software-engineer-agentic-data-pipelines-iambic-therapeutics-inc-united-states-z1afztyyenvn) — United States - [Principal Medical Writer](https://feeny.ai/job/principal-medical-writer-iambic-therapeutics-inc-united-states-p7p8wv9kdmyd) — United States - [Sr Manager, Quality Systems & Compliance](https://feeny.ai/job/sr-manager-quality-systems-compliance-iambic-therapeutics-inc-united-states-vsh166q5vj7e) — United States